Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C

Raffaele Bruno, Paolo Sacchi, Massimo Puoti, Valentina Ciappina, Cristina Zocchetti, Enrico Brunetti, Elena Maffezzini, Anna Capelli, Savino F A Patruno, Antonello Malfitano, Gaetano Filice

Research output: Contribution to journalArticle

Abstract

Background: The standard of care for HCV Hepatitis is the combination of interferon (IFN) plus Ribavirin. In HIV patients the use of this combination therapy may induce drug interactions, and reduces the adherence to HAART. The aim of this study is to evaluate safety and efficacy of a 48 weeks daily dose IFN schedule. Methods: We evaluated 50 coinfected patients; alpha IFN 2a was administered at a dose of 3 MU daily. The baseline values were the following : CD4+ 515 cells/mmc (mean); HIV-RNA

Original languageEnglish
Article number17
JournalBMC Infectious Diseases
Volume2
DOIs
Publication statusPublished - Aug 28 2002

Keywords

  • Coinfection
  • HCV
  • HIV
  • Interferon
  • Ribavirin

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint Dive into the research topics of 'Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C'. Together they form a unique fingerprint.

  • Cite this